Monica T. Hinds

Monica T. Hinds

Auto-generated profile, based on publicly available information

Monica T. Hinds

Department of Biomedical Engineering, Oregon Health and Science University, Portland, Ore

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Acta Biomaterialia
Verified
Journal Article
Closed access
KMKathryn A. McKenna
Kathryn A. McKenna
MHMonica T. Hinds
Monica T. Hinds
RSRebecca C. Sarao
Rebecca C. Sarao
PWPing-Cheng Wu
Ping-Cheng Wu
CMCheryl L. Maslen
Cheryl L. Maslen
KGKenton W. Gregory
Kenton W. Gregory

31 October 2016 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Open access
PDF file
MHMatthew W Hagen
Matthew W Hagen
GGGaurav Girdhar
Gaurav Girdhar
JWJohn Wainwright
John Wainwright
MHMonica T Hinds
Monica T Hinds
Background Flow diverters offer a promising treatment for cerebral aneurysms. However, they have associated thromboembolic risks, mandating chronic dual antiplatelet therapy (DAPT). Shield Technology is a phosphorylcholine surface modification of the Pipeline Embolization Device (PED) flow diverter, which has shown significant reductions in material thrombogenicity in vitro. Objective To compare the thrombogenicity of PED, PED with Shield Technology (PED+Shield), and the Flow-Redirection Endoluminal Device (FRED)—with and without single antiplatelet therapy and DAPT—under physiological flow. Methods An established non-human primate ex vivo arteriovenous shunt model of stent thrombosis was used. PED, PED+Shield, and FRED were tested without antiplatelet therapy, with acetylsalicylic acid (ASA) monotherapy, and with DAPT. Radiolabeled platelet deposition was quantified over 1 hour for each device and total fibrin deposition was also quantified. Results Cumulative statistical analysis showed significantly lower platelet deposition on PED compared with FRED. The same statistical model showed significant decreases in platelet deposition when ASA, clopidogrel, or Shield Technology was used. Direct comparisons of device performances within antiplatelet conditions showed consistent significant decreases in platelet accumulation on PED+Shield relative to FRED. PED+Shield showed significant reductions in platelet deposition compared with unmodified PED without antiplatelet therapy and with DAPT. PED accumulated minimal fibrin with and without Shield Technology. Conclusions In this preclinical model, we have shown that the Shield Technology phosphorylcholine modification reduces the platelet-specific thrombogenicity of a flow diverter under physiologically relevant flow with and without DAPT. We have further identified increased fibrin-driven thrombogenicity associated with FRED relative to PED.

15 July 2011 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
DADeirdre E. J. Anderson
Deirdre E. J. Anderson
MHMonica T. Hinds
Monica T. Hinds

1 October 2015 in Acta Biomaterialia
Verified
Journal Article
Closed access
MCMarie F.A. Cutiongco
Marie F.A. Cutiongco
DADeirdre Anderson
Deirdre Anderson
MHMonica T. Hinds
Monica T. Hinds
EYEvelyn Yim
Evelyn Yim

13 December 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
DSDevon E. Scott-Drechsel
Devon E. Scott-Drechsel
Sandra RugonyiSandra Rugonyi
Sandra Rugonyi
DMDaniel L. Marks
Daniel L. Marks
KTKent L. Thornburg
Kent L. Thornburg
MHMonica T. Hinds
Monica T. Hinds
In pregnant women, the diabetic condition results in a three- to fivefold increased risk for fetal cardiac malformations as a result of elevated glucose concentrations and the resultant osmotic stress in the developing embryo and fetus. Heart development before septation in the chick embryo was studied under two hyperglycemic conditions. Pulsed hyperglycemia induced by daily administration of glucose during 3 days of development caused daily spikes in plasma glucose concentration. In a second model, sustained hyperglycemia was induced with a single injection of glucose into the yolk on day 0. The sustained model raised the average plasma glucose concentration from 70 mg/dL to 180 mg/dL and led to decreased gene expression of glucose transporter GLUT1. Both models of hyperglycemia reduced embryo size, increased mortality, and delayed development. Within the heart outflow tract, reduced proliferation of myocardial and endocardial cells resulted from the sustained hyperglycemia and hyperosmolarity. The cell cycle inhibitor p21 was significantly increased, whereas cyclin D1, a cell cycle promoter, decreased in sustained hyperglycemia compared with controls. The evidence suggests that hyperglycemia-induced developmental delays are associated with slowed cell cycle progression, leading to reduced cellular proliferation. The suppression of critical developmental steps may underlie the cardiac defects observed during late gestation under hyperglycemic conditions.

1 January 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
MPMichael A. Pfeffer
Michael A. Pfeffer
TKTia C.L. Kohs
Tia C.L. Kohs
HVHelen H. Vu
Helen H. Vu
KJKelley R. Jordan
Kelley R. Jordan
SWSi Han Wang
Si Han Wang
JSJoseph J. Shatzel
Joseph J. Shatzel
BACKGROUND: Despite the ubiquitous utilization of central venous catheters in clinical practice, their use commonly provokes thromboembolism. No prophylactic strategy has shown sufficient efficacy to justify routine use. Coagulation factors FXI (factor XI) and FXII (factor XII) represent novel targets for device-associated thrombosis, which may mitigate bleeding risk. Our objective was to evaluate the safety and efficacy of an anti-FXI mAb (monoclonal antibody), gruticibart (AB023), in a prospective, single-arm study of patients with cancer receiving central line placement. METHODS: We enrolled ambulatory cancer patients undergoing central line placement to receive a single dose of gruticibart (2 mg/kg) administered through the venous catheter within 24 hours of placement and a follow-up surveillance ultrasound at day 14 for evaluation of catheter thrombosis. A parallel, noninterventional study was used as a comparator. RESULTS: In total, 22 subjects (n=11 per study) were enrolled. The overall incidence of catheter-associated thrombosis was 12.5% in the interventional study and 40.0% in the control study. The anti-FXI mAb, gruticibart, significantly prolonged the activated partial thromboplastin time in all subjects on day 14 compared with baseline ( P <0.001). Gruticibart was well tolerated and without infusion reactions, drug-related adverse events, or clinically relevant bleeding. Platelet flow cytometry demonstrated no difference in platelet activation following administration of gruticibart. T (thrombin)-AT (antithrombin) and activated FXI–AT complexes increased following central line placement in the control study, which was not demonstrated in our intervention study. CRP (C-reactive protein) did not significantly increase on day 14 in those who received gruticibart, but it did significantly increase in the noninterventional study. CONCLUSIONS: FXI inhibition with gruticibart was well tolerated without any significant adverse or bleeding-related events and resulted in a lower incidence of catheter-associated thrombosis on surveillance ultrasound compared with the published literature and our internal control study. These findings suggest that targeting FXI could represent a safe intervention to prevent catheter thrombosis. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04465760.